HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
10.80
-0.59 (-5.18%)
Jul 30, 2026, 12:47 PM EDT - Market open
HUTCHMED (China) Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 549.12 | 548.51 | 630.2 | 838 | 426.41 | 356.13 |
Revenue Growth | 0.11% | -12.96% | -24.80% | 96.53% | 19.73% | 56.21% |
Gross Profit Gross Profit Growth | 228.19 | 212.16 | 281.32 | 453.55 | 115.31 | 97.89 |
Operating Income Operating Income Growth | -34.78 | -39.16 | -43.71 | 18.38 | -407.69 | -328.32 |
Net Income Net Income Growth | 17.88 | 456.91 | 37.73 | 100.78 | -360.84 | -194.65 |
Earnings Per Share EPS Growth | 0.10 | 2.60 | 0.20 | 0.60 | -2.15 | -1.25 |
EPS Growth | -96.15% | 1200.00% | -66.67% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Ventures Other Ventures Growth | 262.97 | 262.97 | 266.84 | 309.38 | 262.57 | 236.52 |
Oncology/Immunology - Marketed Products Oncology/Immunology - Marketed Products Growth | 214.36 | 214.36 | 271.53 | 164.17 | 124.64 | - |
Oncology/Immunology - R&D Oncology/Immunology - R&D Growth | 71.18 | 71.18 | 91.83 | 364.45 | 39.2 | - |
Total Total Growth | 548.51 | 548.51 | 630.2 | 838 | 426.41 | 356.13 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,375 | 1,367 | 836.11 | 886.34 | 631 | 1,012 |
Total Debt Total Debt Growth | 94.51 | 4.73 | 7.01 | 6.79 | 8.9 | 7.16 |
Net Cash (Debt) Net Cash Growth | 1,280 | 1,363 | 829.1 | 879.55 | 622.09 | 1,005 |
Net Cash Growth | -6.04% | 64.34% | -5.74% | 41.39% | -38.07% | 134.10% |
Net Cash Per Share Net Cash Per Share Growth | 7.33 | 7.80 | 4.75 | 5.06 | 3.67 | 6.34 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 20.46 | -64.66 | 0.5 | 219.26 | -268.6 | -204.22 |
Capital Expenditures CapEx Growth | -10.51 | -14.15 | -17.93 | -32.61 | -36.66 | -16.4 |
Free Cash Flow Free Cash Flow Growth | 9.95 | -78.81 | -17.44 | 186.65 | -305.26 | -220.62 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 41.56% | 38.68% | 44.64% | 54.12% | 27.04% | 27.49% |
Operating Margin | -6.33% | -7.14% | -6.94% | 2.19% | -95.61% | -92.19% |
Pretax Margin | -5.83% | 95.05% | 7.20% | 12.60% | -84.58% | -43.56% |
Profit Margin | -6.13% | 83.45% | 6.06% | 12.06% | -84.52% | -46.90% |
FCF Margin | 1.81% | -14.37% | -2.77% | 22.27% | -71.59% | -61.95% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 4.34 | 5.13 | 72.05 | 30.18 | - | - |
P/FCF Ratio | - | - | - | 16.91 | - | - |
PS Ratio | 3.61 | 4.24 | 3.91 | 3.77 | 5.99 | 17.03 |